https://www.advanzpharma.ca/news/2025/advanz-pharma-acquires-global-rights-to-rare-disease-specialty-brand-zavesca2025-10-13https://www.advanzpharma.ca/news/2025/european-marketing-application-for-avt23-a-proposed-biosimilar-to-xolair-omalizumab-accepted-by-the-european-medicines-agency2025-10-06https://www.advanzpharma.ca/news/2025/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-three-additional-biosimilars-in-europe2025-05-28https://www.advanzpharma.ca/news/2025/advanz-pharma-canada-inc-announces-approval-of-mytolac-in-canada-the-first-generic-lanreotide-for-the-treatment-of-acromegaly-enteropancreatic-neuroendocrine-tumours-nets-and-carcinoid-syndrome2025-03-14https://www.advanzpharma.ca/news/2024/advanz-pharma-acquires-the-rights-to-progynova-and-cyclo-progynova-in-selected-countries-in-apac-from-bayer2024-12-04https://www.advanzpharma.ca/news/2024/european-medicines-agency-confirms-acceptance-of-marketing-authorization-application-for-avt05-a-proposed-biosimilar-to-simponi-golimumab2024-11-04https://www.advanzpharma.ca/news/2024/advanz-pharma-releases-environmental-social-governance-esg-report-for-2023-20242024-10-04https://www.advanzpharma.ca/news/2024/advanz-pharma-and-enzene-enter-an-exclusive-partnership-for-biosimilar-development-and-commercialisation2024-08-27https://www.advanzpharma.ca/news/2024/european-medicines-agency-confirms-acceptance-of-marketing-application-for-avt06-a-proposed-biosimilar-to-eylea-aflibercept2024-08-15https://www.advanzpharma.ca/news/2024/alvotech-and-advanz-pharma-sign-commercialization-agreement-for-proposed-biosimilar-to-eylea-ld-hd-in-europe2024-06-18https://www.advanzpharma.ca/news/2021/advanz-pharma-enters-into-agreement-to-acquire-the-rights-to-eisais-zonegran-in-the-eu-middle-east-russia-and-australia2024-05-30https://www.advanzpharma.ca/news/2021/nordic-capital-acquires-specialty-pharmaceutical-company-advanz-pharma-in-deal-worth-846-million-12024-05-30https://www.advanzpharma.ca/news/2021/nordic-capital-acquires-specialty-pharmaceutical-company-advanz-pharma-in-deal-worth-846-million2024-05-30https://www.advanzpharma.ca/news/2021/embracing-omnichannel-engagement-in-a-virtual-world2024-05-30https://www.advanzpharma.ca/news/2021/advanz-pharma-corp-limited-announces-first-quarter-2021-results2024-05-30https://www.advanzpharma.ca/news/2021/advanz-pharma-and-endo-announce-partnership-for-paladin-labs-to-commercialize-xydalba-dalbavancin-hydrochloride-in-canada2024-05-30https://www.advanzpharma.ca/news/2021/advanz-pharma-corp-limited-announces-fourth-quarter-and-2020-results2024-05-30https://www.advanzpharma.ca/news/2021/advanz-pharma-acquires-the-rights-to-cyclophosphamide2024-05-30https://www.advanzpharma.ca/news/2021/press-announcement-27-january-20212024-05-30https://www.advanzpharma.ca/news/2021/advanz-pharma-corp-limited-announces-agreement-of-terms-to-be-acquired-by-nordic-capital2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-third-quarter-2020-results2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-release-date-for-third-quarter-2020-results2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-advanz-or-the-company-formal-sale-process2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-second-quarter-2020-results2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-release-date-for-second-quarter-2020-results2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-results-of-annual-meeting-of-shareholders2024-05-30https://www.advanzpharma.ca/news/2020/correvio-provides-update-pursuant-to-bci-51-515-temporary-exemption-from-certain-corporate-finance-requirements2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-appoints-new-chief-medical-officer2024-05-30https://www.advanzpharma.ca/news/2020/hydroxychloroquine-supply-update2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-first-quarter-2020-results2024-05-30https://www.advanzpharma.ca/news/2020/update-on-covid-19-virus-12024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-completes-voluntarily-delisting-from-the-toronto-stock-exchange2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-release-date-for-first-quarter-2020-results2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-fourth-quarter-and-2019-results2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-release-date-for-fourth-quarter-and-2019-results2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-to-voluntarily-delist-from-the-toronto-stock-exchange2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-comments-on-cma-supplemental-statement-of-objections-related-to-hydrocortisone-tablets2024-05-30https://www.advanzpharma.ca/news/2020/advanz-pharma-corp-limited-announces-definitive-agreement-to-acquire-the-rights-to-a-portfolio-of-alprostadil-products-from-ucb-s-a-for-approximately-84-million2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-results-of-special-meeting-of-shareholders2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-results-of-annual-meeting-of-shareholders2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-release-date-for-second-quarter-2019-results2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-second-quarter-2019-results2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-release-date-for-third-quarter-2019-results2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-third-quarter-2019-results2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-proposal-to-re-domicile-from-canada-to-europe2024-05-30https://www.advanzpharma.ca/news/2019/industry-related-category-item2024-05-30https://www.advanzpharma.ca/news/2019/corporate-presentation2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-first-quarter-2019-results2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-release-date-for-first-quarter-2019-results2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-acquires-international-rights-to-two-medicines2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-comments-on-cma-supplemental-statement-of-objections2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-release-date-for-fourth-quarter-and-2018-results2024-05-30https://www.advanzpharma.ca/news/2019/advanz-pharma-corp-announces-fourth-quarter-and-fiscal-2018-results2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-adds-european-pharmaceutical-industry-expert-to-its-board-of-directors2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-announces-release-date-for-third-quarter-2018-results2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-provides-further-update-on-its-recently-completed-recapitalization-transaction-and-the-issue-price-of-its-private-placement2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-announces-intention-to-rebrand-as-advanz-pharma-following-its-successful-recapitalization2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-announces-special-meeting-of-shareholders-to-approve-name-change2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-announces-addition-of-pharmaceutical-industry-expert-to-its-board-of-directors2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-announces-release-date-for-second-quarter-2018-results-12024-05-30https://www.advanzpharma.ca/news/2018/third-quarter-2018-results-announced-instead-of-concordia-international-corp-announces-third-quarter-2018-results2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-announces-release-date-for-second-quarter-2018-results2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-announces-nasdaq-delisting2024-05-30https://www.advanzpharma.ca/news/2018/concordia-international-corp-announces-second-quarter-2018-results2024-05-30https://www.advanzpharma.ca/news/2024/advanz-pharma-and-allecra-therapeutics-announce-approval-in-the-european-union-for-the-new-antibiotic-combination-exblifep-cefepime-enmetazobactam-for-the-treatment-of-severe-infections2024-03-27https://www.advanzpharma.ca/news/2021/advanz-pharma-announces-launch-of-mytolac-in-germany-the-first-generic-lanreotide-for-the-treatment-of-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-gep-nets2024-03-22https://www.advanzpharma.ca/news/2021/advanz-pharma-announces-launch-of-myrelez-in-norway-the-first-generic-lanreotide-for-the-treatment-of-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-gep-nets2024-03-22https://www.advanzpharma.ca/news/2021/advanz-pharma-makes-key-changes-to-senior-leadership-to-further-accelerate-next-phase-of-growth2024-03-22https://www.advanzpharma.ca/news/2021/advanz-pharma-launches-its-first-environmental-social-and-governance-report2024-03-22https://www.advanzpharma.ca/news/2024/advanz-pharma-receives-positive-chmp-opinion-for-exblifep-cefepime-enmetazobactam2024-01-26https://www.advanzpharma.ca/news/2023/advanz-pharma-further-strengthens-its-global-portfolio-of-specialty-brands2024-01-19https://www.advanzpharma.ca/news/2023/advanz-pharma-and-dimerix-enter-into-an-exclusive-license-agreement-to-commercialise-dmx-200-in-europe-canada-australia-and-new-zealand2024-01-19https://www.advanzpharma.ca/news/2023/advanz-pharma-signs-an-exclusive-agreement-with-gp-pharm-for-a-peptide-specialty-injectable-generic-for-multiple-european-countries2024-01-19https://www.advanzpharma.ca/news/2023/advanz-pharma-releases-environmental-social-governance-esg-report-for-2022-20232024-01-19https://www.advanzpharma.ca/news/2023/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-five-proposed-biosimilars-in-europe2024-01-19https://www.advanzpharma.ca/news/2023/advanz-pharma-launches-palmeux-paliperidone-1-month-long-acting-injection-across-various-european-countries2024-01-19https://www.advanzpharma.ca/news/2023/advanz-pharma-enters-into-an-exclusive-agreement-with-alvotech-to-commercialise-a-proposed-biosimilar-to-xolair-omalizumab2024-01-19https://www.advanzpharma.ca/news/2023/advanz-pharma-to-receive-exclusive-rights-from-applied-therapeutics-to-commercialise-at-007-govorestat-in-europe2024-01-19https://www.advanzpharma.ca/news/2022/advanz-pharma-further-strengthens-its-specialty-and-hospital-business-by-acquiring-an-anti-infective-portfolio-from-sanofi2024-01-19https://www.advanzpharma.ca/news/2022/advanz-pharma-to-receive-exclusive-rights-from-polypid-to-commercialize-d-plex100-in-europe2024-01-19https://www.advanzpharma.ca/news/2022/advanz-pharma-completes-acquisition-of-intercepts-business-in-europe-canada-and-all-other-markets-outside-of-the-u-s2024-01-19https://www.advanzpharma.ca/news/2022/advanz-pharma-to-acquire-intercepts-business-in-europe-canada-and-all-other-markets-outside-of-the-u-s2024-01-19https://www.advanzpharma.ca/news/2022/steffen-wagner-assumes-his-position-as-new-chief-executive-officer-at-advanz-pharma2024-01-19https://www.advanzpharma.ca/news/2022/cidron-aida-finco-s-%C3%A0-r-l-successful-pricing-of-175-0-million-5-senior-secured-notes-due-20282024-01-19https://www.advanzpharma.ca/news/2022/cidron-aida-finco-s-%C3%A0-r-l-proposed-offering-of-150-million-5-senior-secured-notes-due-20282024-01-19https://www.advanzpharma.ca/news/2022/allecra-therapeutics-and-advanz-pharma-sign-exclusive-license-and-supply-agreement-for-allecras-antibiotic-cefepime-enmetazobactam-in-europe2024-01-19https://www.advanzpharma.ca/news/2023/advanz-pharma-acquires-global-rights-to-androcur-from-bayer2024-01-19